Scorching hot healthcare IPOs net HK$2.7bn

By Jonathan Breen
06 Jul 2020

Mainland-based firms OcuMension Therapeutics and Immunotech Biopharm sealed their Hong Kong IPOs at the top of guidance, riding on support from both institutional and retail investors.

OcuMension specialises in pharmaceutical products for ophthalmology, which focuses on the diagnosis and treatment of eye disorders. It develops and sells therapies for various types of eye diseases. 

The company hit the market last Monday with an offer of 105.9m shares at HK$13.16-HK$14.66 ($1.70-$1.89) per share, eyeing ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial